Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
come on shom...lets get a good pump going here .....I thought you guys were doing a health monitoring wrist watch.....lots of people in your China home base of operations that could use one to monitor for CV19. LOL
At least Thursdays call won't be done by "the next super stock"live
Trademark for Sterabot!!!!!
STERABOT POWERED BY BINARY IONIZATION TECHNOLOGY
TOMI Environmental Solutions, Inc.
USPTO Trademarks › TOMI Environmental Solutions, Inc. › Sterabot Powered By Binary Ionization Technology Application #90065017
Application Filed: 2020-07-21
Trademark Application Details
Trademark Logo STERABOT POWERED BY BINARY IONIZATION TECHNOLOGY
The mark consists of upper-case STERABOT with STERA in large wide font and BOT in large less wide font and underneath the words POWERED BY in smaller sized font and BINARY IONIZATION TECHNOLOGY in larger font.
Mark For: STERABOT POWERED BY BINARY IONIZATION TECHNOLOGY™ trademark registration is intended to cover the category of power-operated sprayers. [all]
Status
2020-07-27 UTC
? Refresh
LIVE APPLICATION Awaiting Examination
The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.
Serial Number 90065017
Mark Literal Elements STERABOT POWERED BY BINARY IONIZATION TECHNOLOGY
Mark Drawing Type -
Mark Type TRADEMARK
Standard Character Claim No
Register PRINCIPAL
Current Location NEW APPLICATION PROCESSING 2020-07-24
Basis 1(b)
Class Status ACTIVE
Primary US Classes
013: Hardware, Plumbing and Steamfitting Supplies
019: Vehicles
021: Electrical Apparatus, Machines and Supplies
023: Cutlery, Machinery, Tools and Parts Thereof
031: Filters and Refrigerators
034: Heating, Lighting and Ventilating Apparatus
035: Belting, Hose, Machinery Packing and Non-Metallic Tires
Primary International Class
007 - Primary Class
(Machinery) Machines and machine tools; motors and engines (except for land vehicles); machine coupling and transmission components (except for land vehicles); agricultural implements other than hand-operated; incubators for eggs.
Filed Use No
Current Use No
Intent To Use Yes
Filed ITU Yes
44D Filed No
44E Current No
66A Current No
Current Basis No
No Basis No
Attorney Name John N. Jennison
Timeline
2020-07-21 Application Filed
2020-07-24 Location: NEW APPLICATION PROCESSING
2020-07-24 Status: Live/Pending
2020-07-24 Status: New application will be assigned to an examining attorney approximately 3 months after filing date.
2020-07-24 Transaction Date
Trademark Ownership
Owner: TOMI Environmental Solutions, Inc.
Address Penthouse 9454 Wilshire Blvd. Beverly Hills, CALIFORNIA UNITED STATES 90212
Legal Entity Type Corporation
Legal Entity State FLORIDA
Documents
Application MULTI 2020-07-21
Drawing JPEG 2020-07-21
Attorney of Record
JOHN N. JENNISON
JENNISON & SHULTZ, P.C.
2001 RICHMOND HWY.
SUITE 1102
ARLINGTON, VA 22202
Good, Services, and Codes
IC 007. US 013 019 021 023 031 034 035. G & S: POWER-OPERATED SPRAYERS
International Codes: 7
U.S. Codes: 013,019,021,023,031,034,035
Type Code Type
DM0000 The mark consists of upper-case STERABOT with STERA in large wide font and BOT in large less wide font and underneath the words POWERED BY in smaller sized font and BINARY IONIZATION TECHNOLOGY in larger font.
Trademark Filing History
Description Date Proceeding Number
NEW APPLICATION ENTERED IN TRAM 2020-07-24
agreed winemaker....beyond 5$ IMO if food safety gets traction ....and based on todays PR, which are rare with TOMI, I would bet on them having something locked up with the industry!!
food safety is HUGE. this could be bigger than any hospital, military, etc applications
this alone , if processors start to buy in, would get us past 5$ IMO
Dr. Yo just said Leronlimab is the grandaddy of all the drugs currently in testing
did results leak by chance ??? nice run up
Lets not forget the young lady that did the video's on YouTube and how she was in the Leronlimab test group and had a full recovery in a short time.....if she is a precursor of what's to be reported in the efficacy results we are in great shape.!!!
look at this lack of news as a buying opportunity before Q2 numbers....load em up!!
Dr Henri Li of Sorrento talking about Cytokine storm on Kramer's Mad Money. .... should help us get the word out about a drug already available called LERONLIMAB!!!!
about time we had day like this !!!! My God, the VOLUME
if I would of known it took days for the stock to react to the Columbia news I would of loaded more to the boat last week!!!! talk about a delayed reaction to a news story
hope they are not to busy to put out their Q2 numbers.....not that's a bad thing considering how many orders they are trying to fill !!!!
last chance to load up imo
NP seemed way to chipper.. DONT THINK HE WOULD DO PROACTIVE IF THINGS WERE NEGATIVE!!!
...I think we are talking efficacy in the 85-95% rate IMO
that would blow away remdesivere and with NO SIDE EFFECTS
My 1.78's only partially filled.....guess not going anywhere but up
Lifelong, great questions...if jtf so disgusted with CYDY just drop it and post on a stock you like and are proud to own....I don't think the FDA cares about NP's 30 year old history, just the data
slow and steady no need to rush to 5$
Wow...what an EOD run....could data from M2M leaking out ??????
these dips are good for our accumulation because they always seem to fill.... especially as we get closer to Q2 numbers
Did I hear that correctly....none of the HIV subjects have acquired Covid
is he saying its just info on the needles used in the test ???? if so tomorrow we will go !!!!
bit dated but from amarex's website. just a reminder
28 May 2020
Amarex Co-Authors Paper on Emergency Use Treatment of Leronlimab for COVID-19
Germantown, MD, USA (May 28, 2020) – In mid-March, Amarex worked with client CytoDyn to prepare, submit, and achieve FDA approval for emergency use of CytoDyn’s drug leronlimab as a treatment for severe cases of COVID-19. Since then, over 50 patients in a New York hospital have been treated with leronlimab. Initial results appear to show that leronlimab restores immune homeostasis, reduces plasma viral load, and reverses hyperimmune activation and inflammation in critically ill COVID-19 patients.
Subsequently, Amarex’s staff co-authored a research paper, in conjunction with CytoDyn,
analyzing the results of the leronlimab treatment. The paper is currently in peer-review. Amarex President & CEO, Dr. Kazem Kazempour, and Senior Vice President of Clinical Operations, Dr. Kush Dhody, are both contributing authors on the paper. The paper is titled Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19, and is available for review at https://www.researchsquare.com/article/rs-26517/v1.
Amarex simultaneously helped CytoDyn with two 'rush' IND applications in order to more definitively assess leronlimab’s effectiveness as a COVID-19 treatment in serious COVID-19 cases and in mild-to-moderate COVID-19 cases. Both applications received approval from the FDA and these studies are currently enrolling subjects. Amarex is providing clinical trial management services for these trials.
Dr. Kazem Kazempour stated, “Considering the novelty of COVID-19, conducting this initial research and achieving these results in less than two months is remarkable. The Amarex team is encouraged by these successes and excited to be directly involved in finding solutions to the COVID-19 pandemic.”
About CytoDyn Inc.
CytoDyn Inc. is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in the first quarter of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients and plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people
wow. what a comeback. approaching 4$
slow and steady rise up....way to do it....avoid over hype.... hopefully a nice buyout offer in the works
would be funny if this is just a stall tactic by FDA so there buddies can get in low b-4 approval given
for breakthrough drug designation....just wild speculation of course
well put evil rabbit....very well put
This is just the start IMO....added manufacturing , little or no debt, relatively low float., excessive demand for product and its required solution.......vary rare for a OTC stock.
I don't think they would do a mid session video call if news was bad....imo
I really doubt trials would be continued if Leronlimab subjects were dying... Im sure we would of had news to that effect and enrollment would have been ceased
I think Samantha from months ago and that recent young lady that did the videos on her recovery are more likely what we are going to see when trial results are unblinded
looks like a bit of a EOD bounce up. GO CYDY
Not to worry...just a few day traders taking little profits....once Q2 news arrives I think we will be easily in the 2-4$ range
Yes, maybe now he has CV-19 we can get Brazil's health dept on board....probably a lot less red tape
I think DR BP keeping a low profile since he knows results and doesn't want to be seen "pumping" a company he's involved with...he seems to me to be a ethical, confident, and humble man.
Any national news coverage on us and we fly past 3.00 IMO. would be there now with help of robin hood traders if they were able to trade OTCBB stocks
don't worry about big dumps.... some people bought well below a dollar and are cashing in.....obviously didnt listen to Q1 CC and what the future holds.... this is one "penny" I don't have to worry about because of quality of product and the endless potential of applications for the product
results hopefully in 2 weeks of so
If we get FDA Approval, where will we see it first ??? on the news feed, from FDA presser, or direct from CYDY release?? or will it be in a Proactive video ???? want to know so can apply more dry powder right when announced for hopefully a ride into the 30's
Death of Nick Cordero IMO could of been avoided with Leronlimab ....did he even had the option?? did his doctors even know there was an option ?? sad these delays occur on life saving options
Wainwright , thanks for the downgrade....doing nothing but help SP go up